Interleukin Genetics Enters Partnership Agreement with Amway Global to Sell Inherent Health Brand of Genetic Tests

Interleukin Genetics Enters Partnership Agreement with Amway Global to Sell
Inherent Health Brand of Genetic Tests

WALTHAM, Mass. and ADA, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Interleukin
Genetics, Inc. (NYSE Amex: ILI) announced today it has entered into an
agreement with Amway Global. With this agreement, Amway Global Independent
Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM)
brand of genetic tests, including the new Weight Management Genetic Test. The
full line will also be available through Interleukin Genetics' e-commerce
site, www.inherenthealth.com.

Interleukin Genetics, Inc. will fulfill and process all Inherent Health
genetic tests through the Company's CLIA-certified laboratory in Waltham, MA.
Amway Global will assist with marketing, implementation and technical
operations related to the sales of genetic tests sold through its
organization.

"We're excited to partner in this new way with Amway Global and work together
to pursue growth opportunities within the personal health and wellness
category," says Lewis H. Bender, CEO, Interleukin Genetics.

"Amway Global has a long-standing commitment to helping people achieve optimal
health and has been ranked the top online health and beauty retailer in the US
for six consecutive years. We feel the Inherent Health line of genetic tests
complement our portfolio of quality products," says Steve Lieberman, Managing
Director of Amway Global.

The Inherent Health suite of genetic tests that Amway Global will now carry
includes:

Weight Management Genetic Test that provides new information beyond
traditional assessments to help individuals understand the genetic factors
that result in better weight management. The test product determines whether
an individual is likely to benefit more from a low fat, low carbohydrate or
balanced calorie reduced diet, and whether an individual is likely to obtain
greater benefit from normal or more vigorous exercise to most efficiently lose
weight based on their genotype.

Heart Health Genetic Test that identifies a person's genetic predisposition
for a certain type of heart disease. The genetic analysis identifies
variations in the IL1 gene, which is associated with inflammation. Excess
inflammation has been implicated as a significant risk factor for heart
disease.

Nutritional Needs Genetic Test that identifies DNA variations in genes crucial
to B-vitamin metabolism and the ability to manage oxidative stress.
Individuals that show suboptimal results for the genes can be at increased
risk for ineffective utilization of B-vitamins and potential for cell damage
caused by oxidative stress.

Bone Health Genetic Test identifies whether an individual is more likely to be
susceptible to spine fractures and low bone mineral density associated with
osteoporosis. This new test is expected to be available by the end of 2009.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests
under the Inherent Health(TM) brand that empower consumers to prevent chronic
diseases of aging, and provides genetic biomarker expertise to assist
pharmaceutical companies in the development and marketing of targeted
therapeutics. The Company leverages its research, intellectual property and
biomarker development experience to facilitate the emerging personalized
health market. Interleukin Genetics is headquartered in Waltham, Mass. For
more information please visit www.ilgenetics.com.

About Amway Global

Amway Global offers the opportunity for people to have a business of their own
based on retailing products and sharing the opportunity with others who will
do the same. Amway Global supports Independent Business Owners (IBOs) with a
proven compensation plan, portfolios of quality products in health, beauty,
and other consumer categories, plus the merchandising materials, training, and
education to help them be successful. IBOs also are supported by communities
of those who have already built successful Amway Global businesses. Based in
Ada, Mich., Amway Global is part of the Alticor group of companies, founded by
the DeVos and Van Andel families. Alticor Inc. is led by Steve Van Andel,
Chairman, and Doug DeVos, President. Global sales for the Alticor group of
companies, which include Amway, Access Business Group, LLC, Alticor Corporate
Enterprises (ACE), and Amway Global, reached $8.2 billion in fiscal 2008.

Certain statements contained herein are "forward-looking" statements,
including statements regarding the expected availability of the Bone Health
Genetic Test. Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to, the risk of market acceptance of the
Company's products, the risk of technology and product obsolescence, delays in
product development, the performance of commercial partners, the availability
of adequate capital, the actions of competitors and other competitive risks,
and those risks and uncertainties described in the Company's annual report on
Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q
and other filings with the Securities and Exchange Commission. The Company
disclaims any obligation or intention to update these forward-looking
statements.

SOURCE Interleukin Genetics, Inc.

Media: Erin Walsh of Interleukin Genetics, +1-781-419-4707,
ewalsh@ilgenetics.com; or Suzanne Fanning of Amway Global, +1-616-787-4985,
suzanne.fanning@amwayglobal.com; or Investor Relations: Stephanie Ascher of
Stern Investor Relations, +1-212-362-1200, stephanie@sternir.com